As a result, Company A now expects to incur $10 million of additional R&D costs and to be reimbursed an additional $10 million by Company B. No other changes were made as part of this amendment. Company A should consider whether the option provided to Company B offers a future discount that is incremental to the range of discounts typically given to the same class of customer. The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct).<\/p>\n
We work on the best accounting software like Xero and Quickbooks, as well as add-ons that will make sure all your work is up-to-date. Set up your accounting software in a day through our checklist, for converting a client from your legacy software to Xero. Compensation arrangements feature complexities with financial statement implications. Cash flow accounting challenges are a leading cause of restatements and SEC comments. Carefully analyzing third-party arrangements is a prerequisite to consolidation conclusions.<\/p>\n
Alternatively, if the economics of the arrangement were such that the payment appeared to be the equivalent of an additional royalty that is paid annually, it may be appropriate to expense the entire $10 million over a 1-year period. This might be the case, for example, if there were similar sales-based milestone targets in each year of the arrangement. In our new report, PwC\u2019s look at four top themes that now affect global healthcare providers, insurers, pharmaceutical and life sciences companies, new entrants… As a result of its strategic partnership, P&G\u2019s business grew from around $400 million in 1990 to more than $4 billion only a decade later. Today, Wal-Mart is by far P&G\u2019s largest customer, representing about $12 billion in sales, or 14 percent of total P&G revenues in 2012. P&G products, in turn, became Wal-Mart\u2019s most profitable\u2014and Wal-Mart was able to capture value without raising prices.<\/p>\n
Company B is in the business of licensing and selling patents in its patent portfolio; therefore, Company A is considered a customer. If Company A is successful in developing a drug and bringing it to the market, Company B will receive a 5% royalty on all sales. The acquired rights apply broadly to the entire territory and, as such, Company A determined that it would account for the acquired right as one unit of account. For unknown reasons, patients in Country X prove far more likely to develop blisters from use of the cream, causing Company A to withdraw the product from that country. As fungicide sales in Country X were not expected to be significant, the loss of the territory, taken in isolation, does not cause the overall value from sales of the drug to be less than its carrying value.<\/p>\n
Furthermore, it\u2019s important for manufacturers to consider the impact of these factors on their gross-to-net process as a whole. Without accurate financial statements, the FDA will not grant approval for a drug to go to market. This is all done against a drug patent\u2019s expiration, so time is of the essence in an already lengthy process.<\/p>\n
Consider the creative collaboration between a leading animal-health pharma company and its customer. In 2000, the pharma company teamed up with a major U.S. swine producer to optimize the producer\u2019s vaccination program through a client-specific study and registry. The pharma company provided dedicated, onsite, technical and medical staff; collected proprietary data; and conducted follow-up research. With the resulting information, the company was able to develop a vaccination program that was tailored to the producer\u2019s swine species, growth program, supplement regime, and other relevant factors.<\/p>\n
Examples cover research and development, intellectual property, manufacturing and supply chain, sales and marketing, revenue recognition, and business combinations. Company A would first allocate the total transaction price of $500 to each performance obligation identified in the contract based on their relative standalone selling price. Based on their standalone selling prices ($450 and $150), this results in 75% ($375) being allocated to the equipment performance obligation and 25% ($125) being allocated to the installation services performance obligation. Companies that participate in government vaccine stockpile programs that do not meet the scope of the interpretive guidance will need to assess whether control of the product has transferred to the government prior to delivery.<\/p>\n
Company B will also receive a royalty of 20% from sales of the HIV compound if Company A successfully develops a marketable drug. Pharmaceutical intangible assets that might be regarded as having an indefinite life could include acquired brands (e.g., over-the-counter products) or generic products. The limited life of patents means that prescription pharmaceutical products and medical devices generally would not have indefinite lives.<\/p>\n
In other words, in the event that a branded drug has a generic or biosimilar option, it will be excluded from the program because the focus is on single-source drugs. Other ineligible drugs include plasma-derived products and orphan-designated drugs approved for a single rare disease. In addition to program integrity, manufacturers\u2019 responsibilities regarding 340B price restatements and refunds to covered entities are growing.<\/p>\n